Xicheng Wang

发表

Identification of Risk Factors Associated with Axillary Lymph Node Metastasis for Sentinel Lymph Node-Positive Breast Cancer Patients

Fan Yang, Zhentao He, X. Lan, 2020, Journal of oncology.

RFA Lowers IDO Activity and Slows Non-Ablated Lesion Growth in Multifocal Hepatic Carcinoma

Jun Dong, Xicheng Wang, Wanlin Tan, 2021 .

A nonendemic analysis of the patterns and prognosis of de novo metastatic nasopharyngeal carcinomas in older patients aged ≥ 65 years

Xicheng Wang, Zhe Wang, Mingxing Zhang, 2022, Scientific Reports.

The prognostic value of B7-H6 in esophageal squamous cell carcinoma

Jun Dong, Xiuyu Cai, Xicheng Wang, 2019, Scientific Reports.

Association of the p 53 or GSTM 1 polymorphism with the risk of nasopharyngeal carcinoma : A meta ‐ analysis

Fan Yang, Xicheng Wang, Wu Muyun, 2022 .

Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial

Ying Sun, Yingqin Li, Y. Mao, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.

Yingqin Li, Y. Mao, Jun Ma, 2019, The New England journal of medicine.

Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

S. Qin, Q. Fan, Xianglin Yuan, 2022, British Journal of Cancer.

PP‐22 promotes autophagy and apoptosis in the nasopharyngeal carcinoma cell line CNE‐2 by inducing endoplasmic reticulum stress, downregulating STAT3 signaling, and modulating the MAPK pathway

Jianwei Jiang, Wan-Jing Cen, Guocai Wang, 2018, Journal of cellular physiology.

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial

Y. Mao, Jun Ma, Liangfang Shen, 2021, The Lancet.

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Ying Cheng, P. Keegan, Baolan Li, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gamma ray‐induced glial activation and neuronal loss occur before the delayed onset of brain necrosis

Yi Li, Jinqing Yang, Honghong Li, 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial

M. Deng, Xiao-jing Du, Shao-xiong Wu, 2019, Journal of Cancer.

Detection of nasopharyngeal carcinoma susceptibility with single nucleotide polymorphism analysis using next-generation sequencing technology

Fan Yang, Xicheng Wang, Shujing Huang, 2017, Oncotarget.

Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy

Lulu Zhang, Y. Xia, Yu-jing Zhang, 2016, Oncotarget.

Intensity-modulated radiotherapy has superior outcomes to three-dimensional conformal radiotherapy in patients with stage IE-IIE extranodal nasal-type natural killer/T-cell lymphoma

Lulu Zhang, Yu-jing Zhang, Xicheng Wang, 2017, Oncotarget.

Association of the p53 or GSTM1 polymorphism with the risk of nasopharyngeal carcinoma: A meta-analysis.

Fan Yang, Xicheng Wang, Dongchen Liu, 2016, Molecular and clinical oncology.

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.

Ying Cheng, Xuhong Min, Yanqiu Zhao, 2022, JAMA.

Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma

Jun Dong, Xiuyu Cai, Xicheng Wang, 2019, BMC Cancer.

Outcomes of Induction Chemotherapy Plus Intensity-Modulated Radiotherapy (IMRT) Versus IMRT Plus Concurrent Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Study

Wuguo Deng, X. Lan, Xicheng Wang, 2016, Translational oncology.

Combined chemotherapy with cisplatin, docetaxel and capecitabine for metastatic nasopharyngeal carcinoma: a retrospective analysis.

Fan Zhang, Xicheng Wang, Xuemei Chen, 2011, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations

Ying Cheng, Baolan Li, Xiao-Li Zhu, 2022, Journal of Clinical Oncology.

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial

Jian Zhou, Chong Zhao, Zhiming Li, 2023, BMC Medicine.

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

H. Pan, Yanqiu Zhao, P. Xing, 2021, Cancer communications.

Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.

Ying Cheng, Xuhong Min, M. Dvorkin, 2022, Journal of Clinical Oncology.

Detection of nasopharyngeal carcinoma susceptibility with single nucleotide polymorphism analysis using next-generation sequencing technology

Fan Yang, Xicheng Wang, Dongchen Liu, 2017, Oncotarget.

Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial

Shun Lu, Yang Zhang, D. Zhong, 2023, Signal transduction and targeted therapy.

Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.

S. Qin, Q. Fan, Xianglin Yuan, 2021, Journal of Clinical Oncology.

Age at diagnosis indicated poor prognosis in locoregionally advanced nasopharyngeal carcinoma.

Wuguo Deng, X. Lan, Xicheng Wang, 2015, Oncotarget.

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.

Ying Sun, Jun Ma, Liangfang Shen, 2021 .

Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC).

Ying Cheng, Wei Zhang, Xiaoqing Liu, 2023, Journal of Clinical Oncology.

The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).

Yunpeng Liu, N. Yang, M. Tao, 2022, Journal of Clinical Oncology.

Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma

Jun Dong, Xiuyu Cai, Xicheng Wang, 2019, BMC Cancer.

Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.

N. Yang, M. Tao, Caicun Zhou, 2021 .

D-1553 (garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients with Non-Small Cell Lung Cancer: Phase I Study Results.

Yanqiu Zhao, N. Yang, Yiping Zhang, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis

Xicheng Wang, Dongxia Wang, Jian Luo, 2023, BMC Cancer.

Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.

Ying Cheng, Baolan Li, Xiao-Li Zhu, 2023, Journal of Clinical Oncology.